| 13.87 Net Asset Value | +0.87% 1 Day | +32.85% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 2.03% Expense Ratio | Above Average Morningstar Risk Rating™ |
| 1 month | +6.61% | 3 years | +31.07% | |
| 3 months | +23.62% | 5 years | +18.03% | |
| 1 year | +52.92% | Since inception | +3.43% |
| FBTBX | Category | |
|---|---|---|
| Performance 5-yr return | +18.03% | +12.10% |
| Expense ratio | 2.03% | 1.55% |
| Risk 5 year sharpe ratio | 0.87 | 0.71 |
| Net assets | $423.5M | $1.5B |
| Average market cap | $10.4B | $19.4B |
| Average P/E | 23.4 | 21.6 |
| Portfolio turnover | 82% | 82% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Fidelity Investments |
| Fund manager & tenure | Rajiv Kaul / 7 Years |
| Minimal initial investment | $2,500.00 |
| Minimum IRA investment | $500.00 |
| Other | 100.00% |
| U.S. stock | -- |
| International stock | -- |
| Fixed income | -- |
| Cash | -- |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| AMGN Amgen Inc | 14.92% |
| GILD Gilead Sciences Inc | 14.56% |
| CELG Celgene Corporation | 7.42% |
| BIIB Biogen Idec Inc | 6.27% |
| ALXN Alexion Pharmaceuticals, Inc. | 3.74% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.58% |
| VRTX Vertex Pharmaceuticals | 3.47% |
| BMRN Biomarin Pharmaceutical, Inc. | 2.99% |
| ONXX Onyx Pharmaceuticals, Inc. | 2.63% |
| MDVN Medivation, Inc. | 1.84% |
.
